Surgical Equipment PE Deals 2026: Why Barriers to Entry Pay.

Surgical equipment platforms are commanding premium multiples in 2026 because the barriers protecting incumbents — FDA clearance pathways, capital-intensive manufacturing, and entrenched hospital purchasing relationships — cannot be replicated by a new entrant inside a five-to-seven-year hold. Apollo, Kohlberg, and Montagu are each pursuing surgical equipment providers for exactly this reason: scarcity of defensible assets, not growth alone, sets the price^[1]. For mid-market sponsors without an existing platform in the category, that scarcity is the real deal problem — not valuation.

Scarcity of defensible assets, not growth, is setting surgical equipment valuations.

Sponsors with existing scale in a sector tend to pay up for barrier-protected add-ons because they already understand what it costs to replicate the barrier from scratch. Reporting on Apollo, Kohlberg, and Montagu's parallel pursuit of surgical equipment providers frames this directly: barriers to entry are an attractive driver for private equity firms that already have a sizeable presence in a sector^[1]. The same dynamic shows up one niche over, in radiopharmaceuticals, where a boom in demand helped Trilantic North America exit SOFIE Biosciences for $945 million^[1] — a healthcare category defined by similarly steep production, licensing, and nuclear-materials-handling barriers that a generalist buyer simply cannot clear in a single hold.

Barriers to entry are the structural costs, certifications, and relationships that make it uneconomic or impossible for a new competitor to replicate an incumbent's position inside a normal private equity hold period. That definition matters because it explains why surgical equipment multiples have decoupled from the sector's underlying revenue growth: buyers are not pricing the next five years of unit sales, they are pricing the near-impossibility of a competitor showing up to compress margins. Three large sponsors converging on the same narrow category simultaneously is itself a data point — it means the number of assets that genuinely clear the bar is smaller than the amount of capital chasing them^[1].

FDA clearance pathways are the first wall, and they are getting taller for new entrants.

Regulatory clearance is the most visible barrier in surgical equipment, and it compounds rather than resets with each new product line. A new entrant attempting to match an incumbent's catalog does not clear one device — it clears a portfolio, each requiring its own 510(k) or PMA pathway, its own clinical validation, and its own post-market surveillance infrastructure, with the quality-management overhead running in parallel across every line simultaneously. The adjacent imaging-AI category illustrates how deep this integration burden runs even for software-only entrants: Sopris Capital's carve-out of Blackford from Bayer involved a radiology orchestration platform that connects more than 130 imaging AI applications from over 45 vendors^[2]. Replicating that vendor and validation web from zero is a multi-year undertaking, not a product launch, and it is the software-only version of the same lock-in a surgical equipment hardware platform carries on a larger scale.

Surgical equipment incumbents carry a version of the same lock-in across hardware, software, and service contracts simultaneously. A platform that already clears the regulatory bar on twenty product lines is not twenty times more valuable than a single-product competitor — it is categorically harder to challenge, because a would-be entrant has to win the same institutional trust, the same clinical validation record, and the same post-market data history on every single line before a hospital system will even evaluate a switch. Buyers price that asymmetry directly into the multiple, which is precisely why the Blackford carve-out and the surgical equipment pursuits described above sit on the same spectrum of a single underwriting question: how long would it take, and how much would it cost, to rebuild this from nothing?

Capital intensity narrows the buyer pool to firms that already have manufacturing and distribution scale.

Manufacturing surgical equipment at hospital-grade reliability requires sterilization infrastructure, inventory depth, and quality-system certification that smaller entrants cannot fund organically. This is why so much of the activity in technically demanding, capital-intensive services shows up as buy-and-build rather than greenfield expansion. LongWater's move to take a majority stake in Blastco to build a national coatings platform is instructive by analogy: Blastco, founded in 1983 and based in Channelview, Texas, provides surface preparation and industrial coatings services that require specialized equipment and certifications a new entrant would need years to assemble^[3]. The sponsor bought existing capacity rather than build it, because building it was the more expensive and slower path — and that calculation only gets more lopsided as the certification requirements get more technical, which is exactly the direction surgical equipment manufacturing has moved.

Surgical equipment buyers reason the same way. A platform with existing manufacturing lines, certified facilities, and qualified suppliers is worth a premium precisely because the alternative — standing up equivalent capacity from scratch — is both capital-intensive and multi-year. That gap between build cost and buy price is where a meaningful share of the platform premium lives, and it is also why sponsors who already own a surgical equipment platform are structurally better buyers of the next one: they can absorb a target's existing manufacturing base into an operating network instead of running it as a standalone, undercapitalized line.

Hospital purchasing relationships are a moat built over decades, not quarters.

Surgical equipment sales run through group purchasing organizations, surgeon preference, and embedded field technicians — relationships that take far longer to establish than any product feature. Stone Point-backed Alliant's acquisition of Melcher & Prescott shows how long these relationship moats can run in regulated distribution businesses generally: the Laconia, New Hampshire broker was founded in 1862 and still operates on relationships that predate most of its current competitors by a century or more^[4]. Distribution trust compounds; it does not transfer with a sales team hire, and a competitor cannot buy its way into a GPO contract that is mid-term.

Scale thresholds reinforce the same point from the buyer's side. Adelis's sale of Danish managed IT provider netIP to Synova involved a business with more than 270 employees across 11 offices^[5] — a footprint large enough to be credible to enterprise buyers, but exactly the kind of density that takes years of regional build-out to replicate. Surgical equipment service networks face an identical threshold: field technician coverage across a hospital system's geography is a prerequisite for the contract, not a nice-to-have, and that coverage cannot be rented for a quarter to win a bid. A new entrant can underprice an incumbent on a single bid and still lose, because the hospital's procurement team is weighing coverage density and historical reliability as much as price.

A worked scenario shows how the barrier stack prices into deal economics.

Consider an illustrative mid-market surgical equipment manufacturer generating $18 million of EBITDA, with a product catalog spanning six cleared device lines and an established field-service network across two regional hospital systems. A generalist buyer with no existing healthcare manufacturing platform underwrites the deal on current cash flow alone, because it has no credible path to defend the margin if a well-funded competitor enters — so it anchors at a conventional lower middle-market multiple and treats the regulatory and distribution assets as a modest adjustment, not a structural moat.

A strategic buyer that already owns a surgical equipment platform underwrites the same target differently. It can fold the six device lines into an existing regulatory and quality-system infrastructure at near-zero marginal integration cost, extend its own field-service network into the target's two hospital systems rather than building parallel coverage, and — critically — knows that no third competitor can replicate either the clearance portfolio or the distribution relationships inside the hold period. That buyer is not paying for $18 million of current EBITDA; it is paying to permanently remove a potential rival from a market with a fixed, small number of credible entrants. The spread between what the generalist buyer will offer and what the strategic buyer will offer is, in practice, the dollar value of the barrier stack itself — and it is why the same target can clear wildly different prices depending entirely on who is bidding, not on what it earns today.

This is the mechanism behind Apollo, Kohlberg, and Montagu each pursuing surgical equipment providers in parallel^[1]: each already owns enough of the barrier stack to extract more value from the next acquisition than a generalist buyer could, which is why the bidding concentrates among a small set of sponsors rather than spreading across the broader buyer universe.

Sponsor competition for scarce, barrier-protected assets is intensifying as public market activism cools.

Capital that would otherwise push into public market campaigns is finding fewer outlets there in 2026, which adds pressure to an already competitive private healthcare bidding environment. Shareholder activism campaign activity came in at 179 launched through Q3 2026 year-to-date, down 7% from 192 a year earlier, with Q3 itself showing a 42% drop to 43 campaigns from 74 in Q2^[6]. A quieter activist calendar does not reduce the pool of capital looking for a home — it redirects some of it toward private platforms with defensible economics, surgical equipment among them.

That redirection shows up directly in the sector: Apollo, Kohlberg, and Montagu pursuing the same category of surgical equipment providers simultaneously is evidence of genuine scarcity, not coincidence^[1]. When three large, well-capitalized sponsors converge on the same narrow set of assets, the binding constraint is not capital — it is the small number of businesses that actually clear the barrier bar. The sequential drop from 74 Q2 campaigns to 43 in Q3^[6] suggests this reallocation is accelerating through the back half of the year, not stabilizing, which points to continued multiple expansion on the smallest tier of qualifying surgical equipment platforms rather than relief.

The barrier stack framework exposes the objections sponsors raise — and where mid-market sourcing should go next.

Mid-market sponsors evaluating a surgical equipment target benefit from scoring the asset against each barrier layer independently, since a weakness in one layer can undercut an otherwise strong platform. A simple Barrier Stack checklist:

• Regulatory clearance depth. How many distinct 510(k)/PMA pathways does the product catalog carry, and how much of that history is non-transferable institutional knowledge rather than documentation?
• Capital and manufacturing lock-in. Could a well-funded competitor replicate current production capacity and certifications within 18 months, or does it require multi-year facility build-out?
• Distribution and relationship depth. What share of revenue sits inside GPO contracts, surgeon-specific relationships, or multi-year service agreements that a new entrant cannot bid into mid-contract?
• Data and software ecosystem lock-in. Does the platform's software, navigation system, or service data create switching costs independent of the hardware itself?

A target that scores strongly across all four layers is the asset Apollo, Kohlberg, and Montagu are chasing^[1]. A target that is strong on regulatory clearance but weak on distribution is a different — and more vulnerable — kind of deal, regardless of what the multiple on offer suggests.

Objection: regulation could loosen and erode the moat.

FDA policy shifts are real, but they move slowly relative to a hold period, and a loosening of clearance requirements would help every incumbent's next product as much as it would help a new entrant's first one. The portfolio effect — twenty cleared lines versus zero — does not disappear even if the marginal clearance gets easier; it just means the next layer of the barrier stack, distribution, becomes the binding constraint instead.

Objection: outsourced manufacturing is eroding the capital barrier.

Contract manufacturing has lowered the floor for building a single device, but it has not solved the integration problem across a multi-line catalog with shared quality systems, shared field-service infrastructure, and shared regulatory history — the same compounding dynamic described above for Blackford's 130-plus application ecosystem^[2]. A contract manufacturer can build the hardware; it cannot manufacture the decade of hospital trust that sits on top of it.

Objection: the multiples already price in scarcity, so late entrants risk overpaying.

This is the most credible objection, and the worked scenario above addresses it directly: the premium a strategic buyer pays reflects real, durable value removed from a smaller competitive set, not sentiment. The risk is not overpaying for a genuinely barrier-protected asset — it is misjudging the barrier stack and paying a strategic premium for a target that is actually closer to the generalist buyer's valuation once distribution or data lock-in is scored honestly.

Scarcity at the top of the market pushes competition down into adjacent, less-obvious surgical equipment and services businesses that have not yet been identified as platforms. When three large sponsors are bidding for the same handful of banked assets, the sourcing advantage shifts to whoever can identify founder-owned, barrier-protected businesses before they reach a formal process. That is consistent with what shows up across other fragmented, technically demanding categories this year — the pattern behind the add-on boom and the broader roll-up economics driving mid-market deployment generally, and it echoes the structural sourcing gap that leaves most proprietary deal flow invisible to teams relying on inbound processes.

For a corp dev team or independent sponsor without an existing surgical equipment platform, the practical takeaway is to stop competing for the banked assets everyone else can see and instead build a thesis-driven map of smaller, barrier-protected businesses — regional device manufacturers, surgical instrument service networks, specialty sterilization providers — before a banker does. Mapping that founder-owned universe is the problem our outbound engine exists to solve.

The barrier dynamics described here are not unique to surgical equipment, but the category concentrates all four layers — regulatory, capital, distribution, and data lock-in — more tightly than almost any other healthcare niche. That concentration is why sponsors with existing sector presence keep paying up for it, and why mid-market players without that presence need a sourcing strategy built around identifying the barrier before the auction does the pricing for them.

FAQ: Surgical Equipment PE Deals and Barriers to Entry